Abstract:The tumor-draining lymph node (TDLN) modulates anti-tumor immunity. Targeting immune checkpoint blockade monoclonal antibodies (mAbs) to the TDLN via subcutaneous (SC) delivery has the potential to enhance efficacy and safety. Recombinant human hyaluronidase (rHuPH20; PH20) transiently removes hyaluronan at interstitial injection sites and is used to facilitate SC delivery of the large doses and volumes required for mAbs. We have previously shown that PH20 co-dosing improves the rate and extent of lymphatic absorption of SC mAbs. Here we investigate whether PH20 co-dosing improves the anti-tumor efficacy of SC anti-CTLA4 (αCTLA4) which targets T cell activation at the TDLN. Efficacy studies and immunophenotyping of the tumor and TDLN were conducted in syngeneic murine tumor models CT26/HAS and MC38/OVA. SC delivery significantly enhanced TDLN uptake of αCTLA4 compared to IV delivery and this was enhanced further by PH20 co-dosing. SC αCTLA4 ± PH20 also more effectively inhibited tumor growth than IV αCTLA4. Importantly, consistent with higher mAb uptake into the TDLN, SC delivery with PH20 enabled a reduction in αCTLA4 dose compared to SC alone or IV (similar efficacy at 3 to 8-fold lower doses). Efficacy improvements occurred concomitantly with greater, more sustained levels of cytotoxic effector CD8+ T cells at the tumor and CD62L+ stem-like CD8+ T cells at the TDLN. The efficacy advantage of SC delivery ± PH20 over IV was limited to TDLN- targeted mAbs. Combination therapy with a non-TDLN targeted mAb, αTIM3, was similarly efficacious across all dose routes. Overall, we report the potential utility of PH20 to improve TDLN-targeted immune checkpoint blockade beyond application as a SC administration enabler. Citation Format: Gracia Gracia, Enyuan Cao, Daniel Yuen, Vilena DM Ferreira, Moore Z Chen, Danielle Senyschyn, Justine D Mintern, Angus PR Johnston, David W Kang, Orlagh M Feeney, Christopher JH Porter. Removal of interstitial hyaluronan facilitates subcutaneous administration and lymphatic delivery of anti-CTLA4 antibody and improves anti- tumor efficacy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B001.

Evidence that Amputation of Bacterial Flagella Does Not Affect Motility.

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer

Hyaluronic acid-conjugated methotrexate and 5-fluorouracil for targeted drug delivery

Tertiary partial 14 trisomy 47, XX, plus 14q minus.

Synthesis and biological evaluation of fluorescent hyaluronic acid modified amorphous calcium phosphate drug carriers for tumor-targeting

Functionalized, Long-Circulating, and Ultrasmall Gold Nanocarriers for Overcoming the Barriers of Low Nanoparticle Delivery Efficiency and Poor Tumor Penetration

Abstract B001: Removal of interstitial hyaluronan facilitates subcutaneous administration and lymphatic delivery of anti-CTLA4 antibody and improves anti- tumor efficacy

Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma

Stromal Barrier-Dismantled Nanodrill-Like and Cancer Cell-Targeted Ph-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin

Hyaluronic acid-targeted dual-bubble/photothermal-driven nanomissile for enhanced "four-in-one" anti-tumor strategy

Integrating Liquification of The Gelated Tumor Interstitium Around Nanomedicines with Biconditional GD2‐targeting for Precise And Safe Chemotherapy

In situ forming an injectable hyaluronic acid hydrogel for drug delivery and synergistic tumor therapy

Therapeutic carrier based on solanesol and hyaluronate for synergistic tumor treatment

Hyaluronidase with pH‐responsive Dextran Modification as an Adjuvant Nanomedicine for Enhanced Photodynamic‐Immunotherapy of Cancer

Fabrication of hyaluronic acid-altered gold complex delivery for head and neck squamous cell carcinoma therapy with high antitumor efficacy and low in vivo toxicity

Silk Nanofiber Carriers for both Hydrophilic and Hydrophobic Drugs to Achieve Improved Combination Chemotherapy

Tumor-targeted delivery of hyaluronic acid/polydopamine-coated Fe2+-doped nano-scaled metal-organic frameworks with doxorubicin payload for glutathione depletion-amplified chemodynamic-chemo cancer therapy

Fabrication of an Injectable Star-polylactide/Thiolated Hyaluronate Hydrogel as a Double Drug-Delivery System for Cancer Treatment

Transformable Honeycomb-Like Nanoassemblies Of Carbon Dots For Regulated Multisite Delivery And Enhanced Antitumor Chemoimmunotherapy